Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to
retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety
profile of the combination therapy. The aim of this study is to evaluate the efficacy and
safety of Cadonilimab monotherapy as neoadjuvant therapy for patients with resectable stage
II-IIIA squamous cell lung cancer.